Skip to main content
Fig. 1 | Genome Medicine

Fig. 1

From: Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

Fig. 1

Agents used for targeted cancer therapy. This figure details the agents discussed in this review, including monoclonal antibodies and kinase inhibitors targeting multiple receptors, including MET, FGFR (fibroblast growth factor receptor), HER2 (human epidermal growth factor receptor 2), EGFR (epidermal growth factor receptor), and ALK (anaplastic lymphoma kinase). Additionally, kinase and phosphatase inhibitors targeting downstream effectors of these receptors are indicated, including SHP2 and members of the PI3K (phosphatidylinositol-3-kinase) and MAPK (mitogen-activated protein kinase) pathways. Lastly, monoclonal antibodies targeting receptors regulating immune response, PD-1 and PD-L1, are also discussed

Back to article page